TRAVERE THERAPEUTICS, INC. Temporary Equity, Foreign Currency Translation Adjustments
TRAVERE THERAPEUTICS, INC. (TVTX) reported Temporary Equity, Foreign Currency Translation Adjustments of $216.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-29.
Discontinued › Shareholders' Equity
us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments · last filed 2021-10-29
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for the quarter ending 2021-09-30 was $216.00K.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for the quarter ending 2021-06-30 was -$227.00K.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for the quarter ending 2021-03-31 was $1.10M, a 477.49% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for the quarter ending 2020-09-30 was -$566.00K, a 279.68% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for fiscal 2018 was $39.00K.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for fiscal 2017 was -$339.00K, a 453.13% decline from fiscal 2016.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for fiscal 2016 was $96.00K.
- TRAVERE THERAPEUTICS, INC. temporary equity, foreign currency translation adjustments for fiscal 2015 was -$40.00K.
| Period end | Temporary Equity, Foreign Currency Translation Adjustments 3 month | Temporary Equity, Foreign Currency Translation Adjustments 6 month | Temporary Equity, Foreign Currency Translation Adjustments 9 month | Temporary Equity, Foreign Currency Translation Adjustments 12 month |
|---|---|---|---|---|
| 2021-09-30 | $216.00K 10-Q · filed 2021-10-29 | -$11.00K derived: sum of 2 quarters · filed 2021-10-29 | $1.09M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | -$227.00K 10-Q · filed 2021-07-29 | $875.00K 10-Q · filed 2021-07-29 | ||
| 2021-03-31 | $1.10M 10-Q · filed 2021-05-06 | |||
| 2020-09-30 | -$566.00K 10-Q · filed 2021-10-29 | -$813.00K derived: sum of 2 quarters · filed 2021-10-29 | -$622.00K 10-Q · filed 2021-10-29 | |
| 2020-06-30 | -$247.00K 10-Q · filed 2021-07-29 | -$56.00K 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $191.00K 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $315.00K 10-Q · filed 2020-11-05 | $224.00K derived: sum of 2 quarters · filed 2020-11-05 | $342.00K 10-Q · filed 2020-11-05 | $351.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$91.00K 10-Q · filed 2020-07-31 | $26.00K 10-Q · filed 2020-07-31 | $36.00K derived: sum of 3 quarters · filed 2020-07-31 | $41.00K derived: sum of 4 quarters · filed 2020-07-31 |
| 2019-03-31 | $117.00K 10-Q · filed 2020-05-11 | $127.00K derived: sum of 2 quarters · filed 2020-05-11 | $132.00K derived: sum of 3 quarters · filed 2020-05-11 | $134.00K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $15.00K derived: sum of 2 quarters · filed 2019-10-30 | $17.00K derived: sum of 3 quarters · filed 2019-10-30 | $39.00K 10-K · filed 2019-02-26 |
| 2018-09-30 | $5.00K 10-Q · filed 2019-10-30 | $7.00K derived: sum of 2 quarters · filed 2019-10-30 | $29.00K 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $2.00K 10-Q · filed 2019-08-06 | $24.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $22.00K 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | -$339.00K 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $96.00K 10-K · filed 2019-02-26 | |||
| 2015-12-31 | -$40.00K 10-K · filed 2018-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |